Testing

Consider the Most Probable Number Method for Bioburden Testing

The MPN method can be useful when traditional bioburden tests won’t work, but it must be clearly understood and carefully implemented.

7 Key Events That Solidified the Liquid Biopsy Market

Seven key trends and events helped make Liquid Biopsy attractive to investors, shareholders, patients, and physicians.

Supplier Stories for the Week of August 5

Here’s what was new in the world of medical device suppliers during the week of August 5.

MDxHealth’s Liquid Biopsy Test Proven to Be Cost-Effective

Researchers found that SelectMDx, a test for prostate cancer, had a cost-savings of $1,694 per patient.

FDA Gets Cancer Test on the Fast Track

Personal Genome Diagnostics received a breakthrough device designation from FDA for the PGDx elio plasma resolve liquid biopsy test.

Lots of Light in the Biophotonics Tunnel

Could recent discoveries in physics advance clinical testing?

Supplier Stories for the Week of July 1

Here’s what was new in the world of medical device suppliers during the week of July 1.

Better Imaging for Prostate Cancer Patients?

Blue Earth Diagnostics shines at the 2018 annual meeting of the Society of Nuclear Medicine and Molecular Imaging, with fleshed out results from the LOCATE trial.

Monitoring is Key in Precipio’s Liquid Biopsy Success

Precipio merged with Transgenomics last year to expand its liquid biopsy prowess.

Supplier Stories for the Week of May 6

Here’s what was new in the world of medical device suppliers during the week of May 6.

GeneSight Weeds Out Ineffective Drug Therapies for Depression

Myriad Genetics presented results from a 24-week study that showed Major Depressive Disorder patients were 50% more likely to achieve remission and 30% more likely to respond to treatment using the GeneSight Psychotropic genetic test.

Supplier Stories for the Week of April 22

Here’s what was new in the world of medical device suppliers during the week of April 22.

Orion Sheds Diagnostic Unit for $200M Plus Milestones

Orion Diagnostica develops Point-of-Care tests and earned about $67 million in sales for its most recent reported year.

Qiagen To Unveil 2 Liquid Biopsy Tests at AACR

Qiagen has developed liquid biopsy panels for prostate and lung cancer and is set to introduce the products at the American Association for Cancer Research annual meeting this week.